SEC Tracker
Get the app

Sangamo Therapeutics SGMOQ

Sangamo Therapeutics: signs a material agreement, reports a bankruptcy or receivership and 2 other items

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Reports a bankruptcy or receivership (1.03)
  • Takes on a new financial obligation (2.03)
  • Announces exit or restructuring costs (2.05)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Sangamo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Monopar Therapeutics MNPR public float $156M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Aclaris Therapeutics ACRS public float $149M, Jun 30, 2025
  4. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025